Page 117 - LIBRO DE PSICOFARMACOLOGÍA

Capítulo 5: Antidepresivos

BIBLIOGRAFÍA

Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM. Effect of

venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.

J Clin Pharmacol 2001; 41(4):443-5

American Psychiatric Association: Practice Guideline for the Treatment of Patients with

Major Depressive Disorder (Revisión). Am J Psychiatry 2000; 157: 4 (Supplement)

Benkert O, Hippius H. Psychiatrische Pharmakotherapie. Berlin, Heidelberg, New York,

Tokyo, Springer-Verlag, 1986

Blier P, Bergeron R. Possible neurobiological mechanism underlying faster onset of
antidepressant action. J Clin Psychiatry 2001; 62: 7-11

Danish University Antidepressant Group: Paroxetine: a selective serotonine reuptake
inhibitor showing better tolerance but weaker effect than clomipramine in a controlled

multicenter study. J Affect Disord 1990; 18:289

Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for

major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin

Psychiatry 2002; 63(4):308-15

Disorders. A Novel Experimental and Therapeutic Approach. JP Sauvanet, S2 Langer y PL

Morselli, eds. Raven Press. New York 1988; pp 139-153.

Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression.
Psychiatr Clin North Amer 1996; 19:179-95

Frank E, Kupfer D, Perel J et al. Three-year outcomes for maintenance therapies in recurrent
depression. Arch Gen Psychiatry 1990; 47:1093-9

Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major
depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002; 63(3):225-

31

115